

Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

UK Multi-Cap strategy

The market concluded that omicron is probably less disruptive to economic growth

- Bank of England unexpectedly increased interest rates for the first time in 3 years
- Stock selection in Healthcare contributed to performance
- Travel and leisure companies rebounded on optimism that omicron would be milder

Chris St John
Portfolio Manager, UK Multi-Cap Strategy

What's happening?

Having started the month with a broad sell-off, owing to concerns over the Omicron variant of Covid, the market gradually came to the conclusion that this strain of the virus is highly transmissible but probably less dangerous, and thus less disruptive to economic growth. A surprising development came in the middle of the month, when the Bank of England (BoE) unexpectedly increased interest rates for the first time in more than 3 years. The BoE described the decision as finely balanced. The lack of clarity on whether Omicron would be inflationary or disinflationary seems to have swung the decision to hike, along with the BoE feeling under pressure from headline inflation which is forecast to peak in Spring 2022 at around/above 6%.

The UK equity markets managed the traditional 'Santa rally' through the final month of 2021 and unlike much of the rest of the year where style, size and currency factors skewed performance, during December the market's advance was broadly spread. The FTSE All Share (+4.68%¹), FTSE 100 (+4.75%¹), & FTSE 250 (ex-Investment Companies, +4.95%¹), while the FTSE Small Cap (ex-Investment companies, +5.83%¹) performed strongest of all. Over the 12 months, the FTSE 100 (+18.40%¹) performed in-line with the FTSE 250 (ex-Investment Companies, +18.35%¹), while the FTSE Small Cap (ex-Investment companies, +31.26%¹) outperformed.

Portfolio positioning and performance

The strategy outperformed the FTSE All Share in December. Stock selection contributed positively to outperformance, particularly within the health care sector where the strategy benefitted from its position in Clinigen. The underweight

¹ Source: Bloomberg

position in the financial sector was also positive. Clinigen's share price rose 54.4% in December on news the company was in advanced talks with Triton Investment Management on a possible takeover offer.

The strategy also benefitted from its positions On the Beach (online retailer of beach holidays) and TI Fluid (manufacturer of automotive parts). Travel and leisure companies, including On the Beach, rebounded in the second half of December on optimism that the omicron variant would be a milder strain of Covid-19.

Detractors over the month include Boohoo Group (an online fashion retailer), Ascential (media business specialising in information services) and Rentokil (the world's largest pest control company). Not holding British American Tobacco also detracted from relative performance. Rentokil pulled back following news that it is to acquire US peer Terminix for approximately US\$6.7bn. Whilst the deal makes strategic sense, the size and unexpected nature of it caused some investor concern.

We used share price volatility to add to core holdings and make reductions.

Outlook

Market direction in 2022 seems likely again to be shaped by Covid and inflation. Central banks performed a U-turn on inflation in 2021, shifting from a reassurance that it would be a "transitory" reflection of the post-lockdowns bounce back to an acceptance that it is more persistent. With expectations that inflation will peak in the Spring, there is the chance that central bank policy mistakes could be made. Striking the right balance between slowing the economy as it recovers and not allowing it to overheat will be hard to achieve, especially while withdrawing other monetary support.

There are, of course, reasons to be optimistic about equities in 2022. Economists are forecasting that global real GDP growth will remain above trend. In addition, global inventory levels remain low and the process of rebuilding them will be a further tailwind through 2022. Earnings forecasts are modestly set and valuations should not be a barrier to further progress following the strong earnings growth in 2021 which brought some multiple compression.

In this environment, we continue to focus on those companies that we believe can compound their earnings and where balance sheet strength is supportive of that growth.

No assurance can be given that the UK Multi-Cap Strategy will be successful. Investors can lose some or all of their capital invested. The UK Multi-Cap strategy is subject to risks including; Equity; Smaller companies risk; Liquidity risk; Investments in small and/or micro-capitalisation universe; Investments in specific countries or geographical zones.

El presente documento y cualquier información y/o datos financieros reseñados en el mismo no suponen invitación o recomendación de adquisición o inversión, ni deben constituir la base para la toma de decisiones inversoras ni de garantía de rentabilidad futura de inversiones financieras y, en ningún caso, está dirigido a clientes minoristas y/o inversores finales. La información contenida en el mismo está destinada a clientes profesionales y contrapartes elegibles tal y como son definidos en tanto en los artículos 205 y 207 del Texto Refundido de la Ley del Mercado de Valores como en las normas MiFID (Directiva sobre Mercados de Instrumentos Financieros) 2004/39/CE, presumiéndose, por tanto, la experiencia, conocimientos y cualificación necesarios para tomar sus propias decisiones de inversión y valorar correctamente sus riesgos y el de sus clientes. Dicha información y datos tienen una finalidad meramente informativa y se recomienda tener un conocimiento más detallado a través de los documentos y folletos inscritos en los organismos nacionales e internacionales de regulación especialmente la toma en consideración y conocimiento del Documento de Datos Fundamentales para el Inversor (DFI). El receptor de esta información debe tener presente que la evolución de las variables económicas y los valores de los mercados financieros pueden cambiar significativamente y ser diferentes a los análisis e indicaciones que figuran en este documento. Los inversores deben tener en cuenta que el mercado financiero es fluctuante y que está sujeto a variaciones y que los tipos de cambio pueden sufrir oscilaciones que incidan directamente en la rentabilidad de las inversiones, tanto al alza como a la baja. No debe tomarse como referencia la rentabilidad pasada del producto pues no implica que se comporte de igual forma en el futuro. Para una mayor información y especialmente para el conocimiento de la disponibilidad de los productos se recomienda visitar las páginas web, www.axa-im.com y www.axa-im.es. Les invitamos a verificar con la sociedad de gestión o directamente en nuestra página web, www.axa-im.com, la lista de países en los que se comercializa el fondo.

AXA INVESTMENT MANAGERS no asume responsabilidad alguna por cualquier acto u omisión derivada del uso de la información facilitada, declinando toda responsabilidad por el uso incorrecto o inadecuado del presente documento.

AXA INVESTMENT MANAGERS PARIS, S.A., SUCURSAL EN ESPAÑA, tiene su domicilio social en Madrid, Paseo de la Castellana núm. 93, 6ª planta, se encuentra inscrita en el Registro Mercantil de Madrid, hoja M-727252, tomo 41006, folio 1; y se encuentra registrada en la CNMV bajo el número 38 como Sociedad gestora UCITS del espacio económico europeo con sucursal.

AXA FUNDS MANAGEMENT, es una sociedad anónima constituida conforme a la legislación vigente en Luxemburgo, con número de Registro en Luxemburgo B 32.223RC, y con domicilio social situado en el nº 49, Avenue J.F. Kennedy L-1885 Luxemburgo.

AXA ROSENBERG MANAGEMENT IRELAND LIMITED es una sociedad de responsabilidad limitada constituida y regulada por las leyes de Irlanda, con domicilio social en 78 Sir John Rogerson's Quay Dublín 2, regulada por el Banco Central de Irlanda y registrada en dicho Estado con el número 310308.

Los subfondos de AXA WORLD FUNDS, SICAV de derecho luxemburgués armonizada domiciliada en 49 Avenue J.F. Kennedy L-1855 (Luxemburgo), registrada en la CSSF y en el Registro Mercantil de Luxemburgo bajo el número B-63.116 están inscritos en la CNMV con el número 239 (*verificar en CNMV las clases registradas).

Los subfondos de AXA ROSENBERG EQUITY ALPHA TRUST, fondo de derecho irlandés armonizado, domiciliado en Dublín 1 (Irlanda) Guiad House Guiad Street registrado en la Ireland Financial Market Authority (IFMA) bajo el número 310308 están inscritos en la CNMV con el número 294 (*verificar en CNMV las clases registradas).

Los subfondos de AXA IM FIXED INCOME INVESTMENT STRATEGIES, Fondo de Inversión de derecho luxemburgués armonizado, domiciliado en 49 Avenue J.F. Kennedy L-1855 (Luxemburgo), autorizado y registrado en la Commission de Surveillance du Secteur Financier CSSF bajo el número 3692 están inscritos en la CNMV con el número 867 (*verificar en CNMV las clases registradas).